This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vasoo, S Search for Related Content PubMed PubMed Citation Articles by Vasoo, S Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Drug-induced lupus: an update

Division of Rheumatology, Department of Medicine, National University Hospital, Singapore; Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore sheila_vasoo{at}nuh.com.sg

Drug-induced lupus erythematosus (DILE) is a lupus-like illness that has been recognized as an entity under environmentally-induced lupus erythematosus, where other agents such as physical (ultra-violet irradiation), chemical (heavy metals, aromatic amines) and food products (alfalfa sprouts) have been implicated. DILE has been accepted as a side effect of therapy with over 80 drugs since its first description in association with sulfadiazine in 1945. The epidemiology and clinical course of SLE and DILE differ markedly and prognosis is generally favourable in the latter although occasional lifethreatening cases have been reported in the literature. Constant pharmacovigilance is crucial for prompt diagnosis and cessation of offending therapy offers the best outcome. This review discusses the clinical presentation, diagnosis of DILE as well as provides an update on postulated pathogenic mechanisms and an overview of implicated drugs.

Key Words: drug-induced • lupus erythematosus

Lupus, Vol. 15, No. 11, 757-761 (2006)
DOI: 10.1177/0961203306070000


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. A. Wetter and M. D. P. Davis Lupus-Like Syndrome Attributable to Anti--Tumor Necrosis Factor {alpha} Therapy in 14 Patients During an 8-Year Period at Mayo Clinic Mayo Clin. Proc., November 1, 2009; 84(11): 979 - 984. [Abstract] [Full Text] [PDF]

				A. Marzano, P Vezzoli, and C Crosti Drug-induced lupus: an update on its dermatologic aspects Lupus, October 1, 2009; 18(11): 935 - 940. [Abstract] [PDF]

				G Guhl, B Diaz-Ley, C Garcia-Garcia, J Fraga, and A Garcia-Diez Chemotherapy-induced subacute lupus erythematosus Lupus, August 1, 2009; 18(9): 859 - 860. [PDF]

				E. L. Williams, S. Gadola, and C. J. Edwards Anti-TNF-induced lupus Rheumatology, July 1, 2009; 48(7): 716 - 720. [Abstract] [Full Text] [PDF]

				B. C. Bockle, M. Baltaci, W. Weyrer, and N. T. Sepp Bortezomib-Induced Lupus Erythematosus Tumidus Oncologist, June 1, 2009; 14(6): 637 - 639. [Full Text] [PDF]

				C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]

				M. Wendt, J. Wohlrab, S. Zierz, and M. Deschauer EFALIZUMAB-INDUCED ISOLATED CEREBRAL LUPUS-LIKE SYNDROME Neurology, January 6, 2009; 72(1): 96 - 97. [Full Text] [PDF]